Jump to any asset
849 assets, updated daily
As of September 16, 2026, DexCom Inc. (DXCM) trades at $86.45. CleaRank Financial AI rates it Buy with a fair value of $86.45, in line with the current price. Wall Street's consensus target is $94.00 across 28 analysts. RSI at 41 is in neutral territory, and the price is above its 50-day average of $82.96.
DexCom Inc. (DXCM)
DexCom Inc. NASDAQ
$86.45
1.770 (2.09%)
At close: Sep 15, 4:00 PM EDT
AI Analyst Consensus
75 / 100
DexCom Inc. (DXCM) is trading at $86.45, with its consensus rating at Buy and a consensus score of 75. The company has demonstrated consistent earnings beats over the past several quarters, including a 14.75% EPS surprise in the quarter to June 2026. Revenue growth remains strong, projected at 10.00% for the current quarter and 12.00% for the full year. Despite moderate insider selling totaling $14.8 million against $1 million in purchases, the overall analyst sentiment remains positive, with a median price target of $94.00, suggesting an 8.7% upside. The company operates in the Medical Devices industry within Healthcare, where it holds a leading position in continuous glucose monitoring technology. Its financial health is supported by a profit margin of 20.12% and an operating margin of 24.33%, though its debt-to-equity ratio of 0.53 is slightly above the sector median.
DXCM Price Analysis
Market Metrics
Open
$84.04
Day Range
$83.26 to $87.36
Prev Close
$84.68
Volume
5.96M
52-Week Range
$54.11 to $92.59
Market Cap
$32.62B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (7% difference), suggesting fair market pricing relative to industry standards.
DXCM Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 5 quarters, DXCM beat estimates 5 times. The stock rose 3 times the next day. Price tends to react positively to beats.
DXCM Analysis
Company's Health
4/5
12-Month Analyst Target
+8.73% Upside
Median of 28 analysts (12-month)
$94.00
AI Technical Analysis
DexCom Inc. (DXCM) is currently trading above its 50-day SMA of $82.96 and its 200-day SMA of $71.62, indicating a generally positive trend. However, the price is currently below its 20-day EMA of $86.63, suggesting some near-term weakness. The RSI is at 41, which is neutral, and the MACD is slightly positive at 0.19, signaling a lack of strong momentum in either direction. Volume has been above average recently, with the latest volume at 5.96 million compared to an average of 3.51 million. Key support levels are near the 50-day SMA, while resistance may be found near recent highs. The neutral RSI and MACD suggest that the stock is not exhibiting extreme overbought or oversold conditions, positioning it for potential consolidation or a gradual move based on fundamental catalysts.
ProTips
- Monitor insider selling activity closely; while currently moderate, a significant increase could signal waning management confidence.
- DexCom's premium valuation metrics, particularly its price-to-sales ratio, suggest that future growth must consistently meet or exceed expectations to justify the current stock price.
- Consider the competition in continuous glucose monitoring; advancements by rivals could impact DexCom's market share and pricing power.
Key Catalysts
Bullish
Consistent Earnings Beats
DexCom Inc. (DXCM) has a history of exceeding analyst EPS estimates, most recently with a 14.75% surprise in the quarter to June 2026, indicating strong operational performance.
Source: Earnings ReportsBullish
Strong Revenue Growth Projections
The company is projected to achieve 10.00% revenue growth in the current quarter and 12.00% for the full year, outpacing sector averages and signaling continued market demand.
Source: Analyst EstimatesBullish
Positive Analyst Sentiment
A significant majority of analysts maintain Buy or Outperform ratings, with a median price target of $94.00, reflecting confidence in the company's future prospects.
Source: Wall Street SummaryBearish
Moderate Insider Selling
Insiders have sold a net $14.8 million in stock against $1 million in purchases, indicating some level of profit-taking or portfolio rebalancing by management.
Source: Insider TransactionsBearish
Premium Valuation Metrics
DexCom's price-to-sales ratio of 6.57 is substantially higher than the sector median of 3.7, suggesting the stock may be overvalued if growth falters.
Source: Company FundamentalsMarket Outlook
DexCom Inc. (DXCM) is expected to continue its growth trajectory, driven by its leading position in the continuous glucose monitoring market and ongoing technological advancements. The base case scenario anticipates the stock to potentially reach its median analyst target price of $94.00 within the next 6-12 months, representing an 8.7% upside from the current price of $86.45. Forward-looking revenue growth estimates of 10-12% for the current year and 11% for next year, coupled with strong analyst conviction, support this outlook. Potential upside catalysts include further market penetration, new product launches, and positive clinical data, which could drive the stock towards its higher analyst targets. Conversely, increased competition, regulatory challenges, or a significant shift in insider sentiment could pressure the stock, potentially leading it towards its lower support levels or even the downside projection of $35.88 from the long-range simulation.
Key Statistics
| Market Cap | 32.62B |
|---|---|
| P/E Ratio | 34.17 |
| EPS (TTM) | 2.53 |
| Dividend Yield | 0.00% |
| 52 Week High | 92.59 |
| 52 Week Low | 54.11 |
DexCom Inc. (DXCM) exhibits a P/E ratio of 34.17, which is above the sector median of 31.9, but its price-to-sales ratio of 6.57 is significantly higher than the sector median of 3.7, indicating a premium valuation. The company's return on equity stands at a strong 38.49%, well above the sector average of 6.9%, and its profit margin of 20.12% and operating margin of 24.33% are strong. While the valuation appears stretched on a P/S basis, the company's superior profitability and growth metrics justify some premium. The revenue growth of 13.1% reported is above the sector average of 8.1%. The debt-to-equity ratio of 0.53 is slightly higher than the sector median, but manageable given the company's strong profitability and cash flow generation.
Earnings & Growth Analysis
DexCom Inc. (DXCM) has a track record of exceeding earnings expectations, most recently reporting an EPS of $0.70 for the quarter to June 2026, surpassing estimates by 14.75% and leading to an 11.95% stock price increase. Prior quarters also show consistent beats, with the quarter to March 2026 EPS coming in at $0.56 against an estimate of $0.47. This pattern of positive earnings surprises suggests strong operational execution and demand for its products.
Key Risks
DexCom Inc. (DXCM) faces valuation risk, with its price-to-sales ratio significantly exceeding the sector median. Moderate insider selling, with total sales of $14.8 million, warrants monitoring, although the overall analyst consensus remains positive. Competition within the continuous glucose monitoring market is intensifying, posing a potential threat to market share and pricing power.
Technical Indicators
| RSI (14) | 41.00 |
|---|---|
| MACD | 0.19 |
| SMA 50 | 82.96 |
| SMA 200 | 71.62 |
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($82.96) above the 200-day SMA ($71.62), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.19
Weak correlation
Nasdaq 100 (QQQ)
+0.16
Weak correlation
Bitcoin (BTC)
+0.10
Weak correlation
Gold (XAU)
+0.04
Weak correlation
Check Custom Correlation
How does any other asset move with DXCM? One year of daily closes, Pearson correlation.
Try
DXCM Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$84.72
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$86.45
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$78.46
MAX LOSS
-7.4%
Volatility-Adjusted Stop Loss
Calculated based on RSI (41.0) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$88.96
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$93.19
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$97.43
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for DXCM is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 16, 2026.Growth of $10,000
A $10,000 investment in DXCM in September 2016 would be worth about $37,159 today, compared with about $35,497 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in DXCM today could grow to about $27,106 by 2036 in the base case, with a bull case near $204,598 and a bear case around $3,591. Projections are statistical simulations, not guarantees.
DXCM Stock Price Prediction: 2030
CleaRank's simulation projects a price near $129 for DXCM by 2030 in the base case, from $86.45 today (1.5x over 4 years). The downside path ends near $35.88. These are outcomes of a Monte Carlo simulation run on DXCM's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $50.40 | $95.51 | $181 |
| 2028 | $42.74 | $106 | $261 |
| 2029 | $38.54 | $117 | $353 |
| 2030 | $35.88 | $129 | $463 |
| 2031 | $34.09 | $142 | $594 |
| 2032 | $32.86 | $157 | $753 |
| 2033 | $32.02 | $174 | $943 |
| 2034 | $31.48 | $192 | $1,171 |
| 2035 | $31.17 | $212 | $1,443 |
| 2036 | $31.04 | $234 | $1,769 |
Method: 10,000 simulated price paths using DXCM's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. DXCM is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
DXCM Insider Trading Analysis
Bought
$1.0M
1 Transactions
Sold
$14.8M
35 Transactions
Insiders
18
Active Traders
Avg Transaction
$438.5K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jan 13, 2021 | SAYER KEVIN R
Chief Executive Officer
|
Sell | 47.0K | $17.0M |
| Sep 15, 2020 | ALTMAN STEVEN R
Director
|
Sell | 30.0K | $11.8M |
| Mar 12, 2024 | SAYER KEVIN R
Chief Executive Officer
|
Sell | 81.0K | $10.8M |
| Sep 10, 2021 | BLACKFORD QUENTIN S
Chief Operating Officer
|
Sell | 18.7K | $10.2M |
| Sep 10, 2020 | BLACKFORD QUENTIN S
Chief Operating Officer
|
Sell | 25.1K | $10.0M |
| Jan 18, 2022 | SAYER KEVIN R
Chief Executive Officer
|
Sell | 22.7K | $9.9M |
| Jun 9, 2021 | LEACH JACOB STEVEN
Chief Technology Officer
|
Sell | 22.8K | $9.0M |
| Jun 22, 2021 | SKYLER JAY S
Director
|
Sell | 20.0K | $8.5M |
| Jun 11, 2020 | LEACH JACOB STEVEN
Chief Technology Officer
|
Sell | 19.1K | $7.2M |
| Apr 8, 2024 | SAYER KEVIN R
Chief Executive Officer
|
Sell | 49.6K | $6.9M |
Page 1 of 1
Frequently Asked Questions
Is DexCom Inc. (DXCM) stock a buy right now?
DexCom Inc. (DXCM) is currently rated a Buy with a consensus score of 75. The stock is trading at $86.45, with a median analyst price target of $94.00, suggesting an 8.7% upside. Consistent earnings beats and strong revenue growth support a positive outlook.
What is DXCM's stock price forecast for 2030?
Based on a Monte Carlo simulation, DexCom Inc. (DXCM) has a base case forecast of $128.82 for 2030, with a downside projection of $35.88 and an upside projection of $462.58. These figures represent statistical outcomes and not definitive price targets.
How does DexCom Inc. compare to its sector peers?
DexCom Inc. (DXCM) operates in the Healthcare sector with a P/E ratio of 34.17 and a P/S ratio of 6.57, both above the sector medians of 31.9 and 3.7 respectively. However, its return on equity (38.49%) and profit margin (20.12%) significantly outperform sector averages.
What are the key catalysts for DexCom Inc. (DXCM)?
Key catalysts include continued innovation in continuous glucose monitoring technology, potential expansion into new markets, and positive clinical trial results. Strong analyst conviction and consistent earnings beats also serve as positive catalysts for the stock.
What are the main risks facing DexCom Inc. (DXCM)?
The primary risks include its premium valuation, particularly its high price-to-sales ratio, and moderate insider selling. Increased competition in the medical device sector and potential regulatory hurdles are also factors to consider.
How has DexCom Inc. performed in recent earnings reports?
DexCom Inc. (DXCM) has consistently beaten earnings estimates, most recently reporting a 14.75% EPS surprise for the quarter to June 2026. This pattern of positive surprises indicates strong operational performance and demand for its products.
What is the outlook for DexCom Inc. (DXCM) over the next 12 months?
The outlook for DexCom Inc. (DXCM) is positive, supported by a Buy consensus rating and a median analyst price target of $94.00. Continued revenue growth projected at 10-12% for the current year and strong forward-looking estimates suggest potential for further appreciation.